Aaron Franke, MD
Hematology & Oncology · Sidney, MTNPI 1730568403
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,675 of the $11,372 with a category attached, or 67.5%. Regeneron accounts for 82.7% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $10,100 and has fallen 97.8% since, to $225 in 2025. Among hematology & oncology clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $324.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$9K
- Myriad Genetic Laboratories, Inc.$375
- Sanofi$224
- AstraZeneca$211
- EMD Serono, Inc.$189
- Johnson & Johnson$165
- plus $804 from 8 others
What the payments were for
- Consulting fees$7,67567%
- Travel & lodging$1,18810%
- Food & beverage$2,34321%
- Education$1651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 14 | $9,403 |
| Myriad Genetic Laboratories, Inc. | 1 | $375 |
| Sanofi | 2 | $224 |
| AstraZeneca | 2 | $211 |
| EMD Serono, Inc. | 2 | $189 |
| Johnson & Johnson | 2 | $165 |
| Eisai Inc. | 2 | $154 |
| Genentech USA, Inc. | 1 | $150 |
| CTI Biopharma Corp. | 1 | $132 |
| Tempus AI, Inc | 2 | $125 |
| Amgen | 2 | $124 |
| Adaptive Biotechnologies Corporation | 2 | $75 |
| Novocure Inc. | 1 | $25 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,372 in reported general payments places this provider in the 90th percentile of 37 hematology & oncology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 12 | $191,336 |
| Abiraterone Acetate | 12 | $32,912 |
| Prochlorperazine Maleate | 34 | $887 |
| Letrozole | 39 | $704 |
| Dexamethasone | 35 | $653 |
| Olanzapine | 18 | $575 |
| Ondansetron OdtOndansetron | 16 | $421 |
| Hydroxyurea | 15 | $348 |
| Prednisone | 30 | $227 |
| Ondansetron Hcl | 22 | $165 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $138 |
| Acyclovir | 12 | $127 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Sidney
- Patrick CobbBillings$21K
- Thomas WeinerHelena$14K
- Carolyn AksHavre$9K
- Karl GuterGreat Falls$9K
- Thomas WarrGreat Falls$8K
- Patrick TangGreat Falls$7K
- Jessica KaaeGreat Falls$6K
- Mark HancockBozeman$6K
- James HueftleAnaconda$5K
- Jennifer CarterGreat Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.